CN113185536A - 一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法 - Google Patents

一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法 Download PDF

Info

Publication number
CN113185536A
CN113185536A CN202110471374.1A CN202110471374A CN113185536A CN 113185536 A CN113185536 A CN 113185536A CN 202110471374 A CN202110471374 A CN 202110471374A CN 113185536 A CN113185536 A CN 113185536A
Authority
CN
China
Prior art keywords
nmr
cdcl
reaction
oxazepine
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110471374.1A
Other languages
English (en)
Other versions
CN113185536B (zh
Inventor
范学森
王慕华
张凌华
张新迎
陈茜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Normal University
Original Assignee
Henan Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Normal University filed Critical Henan Normal University
Priority to CN202110471374.1A priority Critical patent/CN113185536B/zh
Publication of CN113185536A publication Critical patent/CN113185536A/zh
Application granted granted Critical
Publication of CN113185536B publication Critical patent/CN113185536B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms

Abstract

本发明公开了一种吡唑烷酮并苯并1,3‑氧氮杂卓类化合物的合成方法，属于有机合成技术领域。以1‑芳基吡唑烷酮1和重氮萘酮类化合物2为原料，在催化剂、氧化剂和添加剂存在下，有机溶剂中升温反应得到吡唑烷酮并苯并1,3‑氧氮杂卓类化合物3。该方法通过1‑芳基吡唑烷酮类化合物和重氮萘酮类化合物之间发生串联反应，高效地、区域选择性地合成了吡唑烷酮并苯并1,3‑氧氮杂卓类化合物，具有原料简单易得、操作简便、条件温和、选择性好及底物适用范围广等优点。

Description

一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法
技术领域
本发明属于有机合成技术领域，具体涉及一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法。
背景技术
苯并氧氮杂卓是一类重要的同时含氮、氧两种杂原子的稠杂环化合物，该类化合物不仅在自然界中广泛存在，而且许多都具有抗惊厥、抗肿瘤、抗抑郁、抗焦虑、抑菌等生理及药理活性。
目前，该类化合物主要利用双官能团化苯(特别是双卤代苯或单卤代苯等)与其它组分化合物的缩合反应来合成。这些方法尽管相对可靠，但所用原料需要经多步反应制得，成本高且不易得到。另外，反应结束后卤素等原子的丢失也使得反应的原子经济性较低，且产生大量副产物。
因此，研究并开发从简单易得的原料出发，经过简洁的操作来合成苯并1,3-氧氮杂卓类化合物的高效绿色新方法，具有十分重要的理论意义和应用前景。
发明内容
本发明解决的技术问题是提供了一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，该方法通过1-芳基吡唑烷酮类化合物和重氮萘酮类化合物之间发生串联反应，高效地、区域选择性地合成了吡唑烷酮并苯并1,3-氧氮杂卓类化合物，具有原料简单易得、操作简便、条件温和、选择性好及底物适用范围广等优点。
本发明为解决上述技术问题采用如下技术方案，一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，包括如下操作：以1-芳基吡唑烷酮1和重氮萘酮类化合物2为原料，在催化剂、氧化剂和添加剂存在下，有机溶剂中升温反应得到吡唑烷酮并苯并1,3-氧氮杂卓类化合物3，反应方程式为：
Figure BDA0003045535120000011
其中R1为氢、卤素、三氟甲基、氰基、C1-4烷基、C1-4烷氧基或苄氧基，R2为氢、卤素、氰基、乙酰基、苄基、C1-4烷基、C1-4烷氧基、苯基或取代苯基，取代苯基的取代基为卤素、三氟甲基、氰基、乙酰基、C1-4烷基或C1-4烷氧基。
进一步地，在上述技术方案中，所述反应溶剂为起到溶解原料的作用，优选1,2-二氯乙烷、二氯甲烷、乙腈或甲苯。
进一步地，在上述技术方案中，所述氧化剂为醋酸银、过氧化银、三氟乙酸银、碳酸银、氧化铜、醋酸铜或硫酸铜。
进一步地，在上述技术方案中，所述添加剂为醋酸、三甲基乙酸、2,4,6-三甲基苯甲酸或1-金刚烷甲酸。
进一步地，在上述技术方案中，所述催化剂为二氯(五甲基环戊二烯基)合铑(III)二聚体([RhCp*Cl2]2)、五甲基环戊二烯基醋酸铑(III)(RhCp*(OAc)2)、(五甲基环戊二烯基)二氯化铱(III)二聚体([IrCp*Cl2]2)或二(六氟锑酸)三乙腈(五甲基环戊二烯基)铑(III)(RhCp*(MeCN)3(SbF6)2)。
进一步地，在上述技术方案中，所述的1-芳基吡唑烷酮1、重氮萘酮类化合物2、氧化剂、添加剂和催化剂的投料摩尔比为1:1-1.5:1.0-2.5:0.5-3.0:0.025。
进一步地，在上述技术方案中，所述反应温度为60-120℃。
进一步地，在上述技术方案中，反应中额外添加分子筛(例如
Figure BDA0003045535120000021
分子筛)，产率明显提高。
进一步地，在上述技术方案中，反应在氩气氛围下进行。
发明有益效果：
本发明与现有技术相比具有以下优点：(1)合成过程简单、高效，通过1-芳基吡唑烷酮和重氮萘酮类化合物的一锅串联反应，即可高选择性地合成吡唑烷酮并苯并1,3-氧氮杂卓类化合物；(2)原料价廉易得；反应条件温和，操作简便；(3)反应的原子经济性高，符合绿色化学的要求。
说明书附图
图1为实施例2中化合物3a的X-射线单晶衍射图。
具体实施方式
以下通过实施例对本发明的上述内容做进一步详细说明，但不应该将此理解为本发明上述主题的范围仅限于以下的实施例，凡基于本发明上述内容实现的技术均属于本发明的范围。
实施例1
在氩气氛围下，向15mL反应瓶中依次加入1a、2a、有机溶剂、氧化剂、添加剂和催化剂，盖上塞子密封，将其置于油浴中升温搅拌反应。待反应结束后，冷却至室温，萃取，干燥，旋干，过硅胶柱分离(石油醚/乙酸乙酯＝3/1)得白色固体产物3a。反应方程式表示为：
Figure BDA0003045535120000031
通过改变反应溶剂、氧化剂、添加剂、催化剂、反应温度和反应物之间当量比等反应条件，实验结果见表1。
表1不同反应条件下3a的合成a
Figure BDA0003045535120000032
Figure BDA0003045535120000041
实施例2
Figure BDA0003045535120000042
氩气氛围下，向15mL反应瓶中依次加入1a(57.0mg,0.3mmol)、2a(76.5mg,0.45mmol)、乙腈(3mL)、[RhCp*Cl2]2(4.7mg,0.0075mmol)、醋酸银(100.1mg,0.6mmol)和2,4,6-三甲基苯甲酸(98.5mg,0.6mmol)，盖上塞子密封，将其置于100℃油浴中搅拌反应12小时，待反应结束后，冷却至室温，萃取，干燥，旋干，过硅胶柱分离(石油醚/乙酸乙酯＝3/1)得白色固体产物3a(74.3mg,75％)。X-射线单晶衍射图为图1。mp 244.8-245.7℃.1H NMR(600MHz,CDCl3):δ8.13-8.12(m,1H),8.10(s,1H),7.91-7.89(m,1H),7.86(d,J＝9.0Hz,1H),7.57(dd,J1＝7.8Hz,J2＝1.8Hz,1H),7.50-7.47(m,3H),7.42-7.39(m,1H),7.28(d,J＝9.0Hz,1H),7.23(td,J1＝7.8Hz,J2＝1.2Hz,1H),5.52(s,1H),1.29(s,3H),1.13(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,151.2,146.5,132.6,132.0,131.5,130.2,128.8,128.6,128.4,126.9,125.6,125.4,124.6,122.8,119.7,115.9,109.2,43.6,21.4,18.7.HRMS(ESI)m/z:[M+Na]+Calcd for C21H18N2NaO2 353.1260；found 353.1256.
实施例3
依照实施例2的方法和步骤，通过改变反应物1和2，合成出各种吡唑烷酮并苯并1,3-氧氮杂卓类化合物3，具体结果见表2。
表2各种吡唑烷酮并苯并1,3-氧氮杂卓类化合物3的合成a,b
Figure BDA0003045535120000051
代表性产物表征数据如下：
8,8,14-Trimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3b)
White solid(68.1mg,66％),mp 241.2-242.2℃.1H NMR(400MHz,CDCl3):δ8.14-8.12(m,1H),8.08(s,1H),7.89-7.86(m,1H),7.82(d,J＝8.8Hz,1H),7.51-7.45(m,2H),7.37(d,J＝1.2Hz,1H),7.34(d,J＝8.4Hz,1H),7.25(s,1H),7.19(dd,J1＝8.4Hz,J2＝1.6Hz,1H),5.45(s,1H),2.39(s,3H),1.27(s,3H),1.12(s,3H).13C{1H}NMR(100MHz,CDCl3):δ178.3,151.2,144.1,132.6,132.5,132.2,131.5,130.1,129.4,128.6,128.5,126.8,125.7,125.4,124.4,119.8,115.9,108.9,43.5,21.5,20.8,18.8.HRMS(ESI)m/z:[M+Na]+Calcd for C22H20N2NaO2 367.1417；found 367.1405.
14-Ethyl-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3c)
Light yellow solid(64.5mg,60％),mp 195.6-196.5℃.1H NMR(600MHz,CDCl3):δ8.15-8.13(m,1H),7.90(dd,J1＝7.2Hz,J2＝3.0Hz,1H),7.87(d,J＝9.0Hz,1H),7.52-7.47(m,3H),7.41(d,J＝1.8Hz,1H),7.39(d,J＝8.4Hz,1H),7.31(d,J＝8.4Hz,1H),7.23(dd,J1＝8.4Hz,J2＝2.4Hz,1H),5.54(s,1H),2.70(q,J＝7.8Hz,2H),1.31(s,3H),1.29(t,J＝7.8Hz,3H),1.15(s,3H).13C{1H}NMR(100MHz,CDCl3):δ178.2,151.2,144.2,138.7,132.6,131.54,131.46,130.1,128.59,128.57,128.2,126.9,125.6,125.4,124.5,119.8,115.8,109.0,43.5,28.2,21.5,18.8,15.7.HRMS(ESI)m/z:[M+H]+Calcd for C23H23N2O2359.1754；found 359.1750.
14-Methoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3d)
White solid(76.7 mg,71％),mp 221.7-222.7℃.1H NMR(600 MHz,CDCl3):δ8.40(s,1H),8.17-8.16(m,1H),7.87-7.86(m,1H),7.79(d,J＝9.0 Hz,1H),7.49-7.45(m,2H),7.34(d,J＝9.0 Hz,1H),7.22(d,J＝9.0Hz,1H),7.13(d,J＝2.4Hz,1H),6.93(dd,J1＝9.0Hz,J2＝2.4 Hz,1H),5.35(s,1H),3.80(s,3H),1.24(s,3H),1.10(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.4,155.4,151.3,139.9,132.5,131.4,130.3,128.6,128.2,127.0,125.7,125.5,125.4,119.9,117.9,116.9,113.7,108.6,55.7,43.3,21.6,18.9.HRMS(ESI)m/z:[M+Na]+Calcd for C22H20N2NaO3 383.1366；found383.1370.
14-(Benzyloxy)-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3e)
White solid(85.1mg,65％),mp 213.7-214.4℃.1H NMR(600MHz,CDCl3):δ7.99(d,J＝8.4Hz,1H),7.89-7.86(m,2H),7.53(s,1H),7.47-7.38(m,7H),7.35(t,J＝7.2Hz,1H),7.30(d,J＝9.0Hz,1H),7.20(d,J＝2.4Hz,1H),7.05(dd,J1＝8.4Hz,J2＝1.8Hz,1H),5.50(s,1H),5.11(d,J＝12.0Hz,1H),5.07(d,J＝12.0Hz,1H),1.31(s,3H),1.14(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.4,154.5,151.2,140.2,137.0,132.5,131.3,130.4,128.7,128.6,128.1,128.0,127.5,127.1,125.7,125.43,125.41,119.8,118.6,116.9,115.3,108.9,70.4,43.3,21.6,18.8.HRMS(ESI)m/z:[M+H]+Calcd for C28H25N2O3 437.1860；found 437.1863.
14-Fluoro-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3f)
White solid(68.9mg,66％),mp 239.2-240.1℃.1H NMR(600MHz,CDCl3):δ8.11(d,J＝7.8Hz,1H),7.95(s,1H),7.91-7.89(m,2H),7.54-7.49(m,2H),7.44-7.42(m,1H),7.31-7.30(m,2H),7.11(t,J＝7.2Hz,1H),5.51(s,1H),1.30(s,3H),1.13(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.5,158.8(d,1JC-F＝240.6Hz),151.4,142.6(d,4JC-F＝2.1Hz),132.5,131.2,130.9,128.7,127.3,127.2,126.2(d,3JC-F＝7.7Hz),125.7,125.1,119.7,118.6(d,2JC-F＝24.0Hz),117.1(d,3JC-F＝8.7Hz),115.2(d,2JC-F＝21.9Hz),109.1,43.5,21.5,18.8.19F NMR(565MHz,CDCl3):δ-126.99–-127.02(m).HRMS(ESI)m/z:[M+H]+Calcdfor C21H18FN2O2 349.1347；found 349.1356.
14-Chloro-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3g)
White solid(84.1mg,77％),mp 259.2-260.1℃.1H NMR(600MHz,CDCl3):δ8.09(d,J＝8.4Hz,1H),7.92(d,J＝8.4Hz,2H),7.56-7.50(m,4H),7.44(d,J＝9.0Hz,1H),7.37(dd,J1＝9.0Hz,J2＝2.4Hz,1H),7.32(d,J＝9.0Hz,1H),5.56(s,1H),1.32(s,3H),1.14(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,151.4,145.2,132.5,131.5,131.2,130.9,128.7,128.5,128.2,127.4,127.0,126.2,125.7,125.0,119.7,117.2,109.3,43.6,21.3,18.8.HRMS(ESI)m/z:[M+H]+Calcd for C21H18ClN2O2 365.1051；found 365.1050.
14-Bromo-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3h)
White solid(86.9mg,71％),mp 262.7-263.4℃.1H NMR(400MHz,CDCl3):δ8.09(d,J＝8.4Hz,1H),7.91(d,J＝8.8Hz,2H),7.69(d,J＝1.6Hz,1H),7.57-7.51(m,4H),7.38(d,J＝8.8Hz,1H),7.31(d,J＝8.8Hz,1H),5.56(s,1H),1.32(s,3H),1.14(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.2,151.4,145.8,134.3,132.5,131.5,131.2,131.0,128.7,127.5,126.9,126.6,125.7,125.0,119.6,117.6,115.6,109.3,43.6,21.3,18.8.HRMS(ESI)m/z:[M+H]+Calcd for C21H18BrN2O2 409.0546；found409.0548.
8,8-Dimethyl-14-(trifluoromethyl)-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3i)
Yellow solid(69.3mg,58％),mp 206.1-207.1℃.1H NMR(600MHz,CDCl3):δ8.11(s,1H),8.01(d,J＝8.4Hz,1H),7.93(d,J＝8.4Hz,2H),7.82(d,J＝1.8Hz,1H),7.66(dd,J1＝9.0Hz,J2＝1.8Hz,1H),7.59(d,J＝8.4Hz,1H),7.56-7.51(m,2H),7.32(d,J＝9.0Hz,1H),5.61(s,1H),1.32(s,3H),1.14(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.4,151.6,149.5,132.6,131.3,131.1,129.0(q,3JC-F＝3.3Hz),128.8,127.6,127.0,125.79(q,3JC-F＝3.3Hz),125.78,124.9(q,2JC-F＝32.9Hz),124.8,124.3(q,1JC-F＝270.2Hz),119.6,116.0,109.6,43.9,21.0,18.7.19F NMR(376MHz,CDCl3):δ-61.75(s).HRMS(ESI)m/z:[M+H]+Calcdfor C22H18F3N2O2399.1315；found 399.1313.
8,8-Dimethyl-9-oxo-7a,8,9,10-tetrahydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepine-14-carbonitrile(3j)
Yellow solid(66.1mg,62％),mp 266.1-266.7℃.1H NMR(400MHz,CDCl3):δ8.41(s,1H),7.98-7.92(m,3H),7.83(d,J＝2.0Hz,1H),7.65(dd,J1＝8.8Hz,J2＝2.0Hz,1H),7.59-7.52(m,3H),7.31(d,J＝8.8Hz,1H),5.63(s,1H),1.31(s,3H),1.13(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,151.3,147.8,134.7,133.0,132.6,131.4,130.6,128.7,127.4,127.1,125.6,125.2,123.0,122.9,119.6,116.2,109.3,43.7,21.2,18.8.HRMS(ESI)m/z:[M+Na]+Calcd for C22H17N3NaO2378.1213；found 378.1203.
13-Chloro-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3k)
White solid(78.6mg,72％),mp 213.4-214.2℃.1H NMR(400MHz,DMSO-d6):δ10.3(s,1H),8.12-8.08(m,2H),8.02-8.00(m,1H),7.63-7.56(m,3H),7.49(d,J＝8.8Hz,1H),7.37(d,J＝2.0Hz,1H),7.31(dd,J1＝8.0Hz,J2＝1.6Hz,1H),5.70(s,1H),1.24(s,3H),1.01(s,3H).13C{1H}NMR(150MHz,DMSO-d6):δ176.3,151.7,148.9,133.8,133.6,132.6,131.2,131.1,129.3,127.9,127.2,126.1,125.0,122.8,122.5,120.6,116.1,108.8,43.6,21.2,19.3.HRMS(ESI)m/z:[M+Na]+Calcd for C21H17ClN2NaO2 387.0871；found 387.0879.
13-Bromo-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3l)
White solid(80.8mg,66％),mp 265.4-266.4℃.1H NMR(400MHz,CDCl3):δ8.05-8.04(m,1H),7.90(d,J＝8.4Hz,2H),7.65(br s,2H),7.51-7.49(m,2H),7.42(d,J＝8.4Hz,1H),7.35(d,J＝8.4Hz,1H),7.31(d,J＝8.8Hz,1H),5.57(s,1H),1.33(s,3H),1.18(s,3H).13C{1H}NMR(100MHz,CDCl3):δ178.3,151.3,147.8,133.2,132.6,131.3,130.7,128.7,127.4,127.2,125.9,125.6,125.2,123.5,122.7,119.7,119.0,109.4,43.7,21.2,18.8.HRMS(ESI)m/z:[M+H]+Calcd for C21H18BrN2O2409.0546；found 409.0551.
13-Fluoro-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3m)
White solid(63.7mg,61％),mp 216.8-217.7℃.1H NMR(400MHz,CDCl3):δ8.10-8.06(m,2H),7.92-7.89(m,2H),7.51-7.49(m,2H),7.31(d,J＝8.8Hz,2H),7.15-7.11(m,2H),5.38(s,1H),1.34(s,3H),1.27(s,3H).13C{1H}NMR(150MHz,CDCl3):δ176.3,154.8(d,1JC-F＝250.0Hz),151.6,132.8(d,4JC-F＝2.1Hz),132.6,131.5,130.8,128.6,128.5,128.4,128.0(d,3JC-F＝3.3Hz),127.6,127.1,125.5(d,2JC-F＝12.2Hz),123.2(d,3JC-F＝8.7Hz),119.6,117.5(d,2JC-F＝23.0Hz),109.3,44.0,21.5,17.9.19F NMR(376MHz,CDCl3):δ-126.91–-126.96(m).HRMS(ESI)m/z:[M+H]+Calcd for C21H18FN2O2 349.1347；found349.1338.
3-Ethyl-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3n)
White solid(73.1mg,68％),mp 245.4-246.2℃.1H NMR(400MHz,CDCl3):δ8.05-8.02(m,2H),7.77(d,J＝8.8Hz,1H),7.67(s,1H),7.55(d,J＝7.6Hz,1H),7.46(d,J＝8.0Hz,1H),7.40-7.34(m,2H),7.25-7.19(m,2H),5.48(s,1H),2.81(q,J＝7.2Hz,2H),1.33(t,J＝7.2Hz,3H),1.27(s,3H),1.12(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,150.7,146.5,141.4,132.9,131.9,129.9,129.7,128.7,128.1,126.2,125.5,124.8,122.8,119.6,115.8,109.2,43.6,28.8,21.4,18.7,15.5.HRMS(ESI)m/z:[M+Na]+Calcd forC23H22N2NaO2 381.1573；found 381.1571.
8,8-Dimethyl-3-propyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3o)
White solid(73.7mg,66％),mp 217.8-218.1℃.1H NMR(400MHz,CDCl3):δ8.03(d,J＝8.8Hz,1H),7.80-7.78(m,2H),7.66(s,1H),7.57(d,J＝7.6Hz,1H),7.47(d,J＝8.0Hz,1H),7.41-7.33(m,2H),7.26-7.20(m,2H),5.52(s,1H),2.75(t,J＝7.6Hz,2H),1.78-1.69(m,2H),1.29(s,3H),1.13(s,3H),0.98(t,J＝7.2Hz,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,150.6,146.5,139.8,132.8,131.9,129.9,129.7,128.7,128.5,128.1,127.1,125.4,124.8,122.8,119.6,115.8,109.2,43.6,37.9,24.4,21.4,18.7,13.9.HRMS(ESI)m/z:[M+Na]+Calcd for C24H24N2NaO2 395.1730；found 395.1719.
8,8-Dimethyl-3-phenyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3p)
Yellow solid(74.3mg,61％),mp 259.6-260.2℃.1H NMR(600MHz,CDCl3):δ8.10(d,J＝8.4Hz,1H),8.02(d,J＝1.2Hz,1H),7.84(d,J＝9.0Hz,1H),7.67-7.64(m,4H),7.53-7.52(m,1H),7.43-7.41(m,3H),7.36-7.31(m,2H),7.25(d,J＝9.0Hz,1H),7.19-7.17(m,1H),5.49(s,1H),1.24(s,3H),1.07(s,3H).13C{1H}NMR(100MHz,CDCl3):δ178.3,151.3,146.6,140.6,138.1,132.9,132.0,130.6,130.5,129.0,128.9,128.3,127.6,127.4,126.6,126.3,126.2,124.6,122.9,120.2,115.9,109.2,43.6,21.4,18.7.HRMS(ESI)m/z:[M+H]+Calcd for C27H23N2O2 407.1754；found 407.1756.
3-(2-Fluorophenyl)-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3q)
White solid(91.6mg,72％),mp 251.2-252.1℃.1H NMR(400MHz,CDCl3):δ8.12(d,J＝8.8Hz,1H),8.01(s,1H),7.87(d,J＝8.8Hz,1H),7.63(dt,J1＝8.8Hz,J2＝1.6Hz,1H),7.55(dd,J1＝7.6Hz,J2＝1.2Hz,1H),7.49(td,J1＝7.6Hz,J2＝1.6Hz,1H),7.44(d,J＝8.0Hz,1H),7.38-7.34(m,1H),7.32-7.28(m,2H),7.21-7.18(m,2H),7.16-7.11(m,2H),5.53(s,1H),1.27(s,3H),1.09(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.1,160.0(d,1JC-F＝246.2Hz),151.5,146.6,133.0,132.6,132.0,130.9(d,4JC-F＝3.3Hz),130.7,130.6,129.3(d,3JC-F＝7.7Hz),128.9,128.7(d,4JC-F＝2.3Hz),128.6(d,2JC-F＝13.1Hz),128.4,128.1(d,4JC-F＝3.3Hz),125.7,124.56(d,3JC-F＝9.9Hz),124.55,123.0,120.2,116.3(d,2JC-F＝23.0Hz),115.9,109.4,43.6,21.4,18.7.19F NMR(376MHz,CDCl3):δ-117.69–-117.81(m).HRMS(ESI)m/z:[M+H]+Calcd for C27H22FN2O2 425.1660；found 425.1661.
3-Bromo-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3r)
White solid(77.1mg,63％),mp 251.8-252.5℃.1H NMR(400MHz,CDCl3):δ8.06(s,1H),7.97(d,J＝8.8Hz,1H),7.90(s,1H),7.77(d,J＝8.4Hz,1H),7.56-7.42(m,4H),7.33-7.24(m,2H),5.54(s,1H),1.30(s,3H),1.13(s,3H).13C{1H}NMR(100MHz,CDCl3):δ178.2,151.4,146.6,133.7,131.9,130.5,130.2,130.0,129.2,129.1,128.9,127.4,124.1,123.0,121.0,119.6,116.0,109.2,43.6,21.4,18.7.HRMS(ESI)m/z:[M+H]+Calcdfor C21H18BrN2O2 409.0546；found 409.0541.
8,8-Dimethyl-9-oxo-7a,8,9,10-tetrahydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepine-3-carbonitrile(3s)
White solid(75.6mg,71％),mp 261.4-262.3℃.1H NMR(400MHz,DMSO-d6):δ10.20(s,1H),8.12-8.09(m,2H),8.05(d,J＝8.8Hz,1H),7.71-7.69(m,1H),7.52-7.47(m,3H),7.41(d,J＝8.0Hz,1H),7.27(t,J＝7.2Hz,1H),5.63(s,1H),1.20(s,3H),0.95(s,3H).13C{1H}NMR(150MHz,CDCl3):δ176.3,152.3,147.5,132.4,131.7,131.5,131.1,130.9,129.7,129.0,127.8,127.1,123.4,122.9,121.5,121.4,116.6,108.8,43.4,21.5,19.2.HRMS(ESI)m/z:[M+H]+Calcd for C22H18N3O2 356.1394；found 356.1376.
3-Acetyl-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3t)
White solid(78.2mg,70％),mp 259.1-260.1℃.1H NMR(400MHz,CDCl3):δ8.45(d,J＝1.2Hz,1H),8.11(d,J＝9.2Hz,1H),7.96(d,J＝8.4Hz,2H),7.45(d,J＝7.6Hz,2H),7.39-7.31(m,3H),7.21-7.17(m,1H),5.54(s,1H),2.67(s,3H),1.27(s,3H),1.08(s,3H).13C{1H}NMR(150MHz,CDCl3):δ197.8,178.1,153.1,146.6,134.0,133.9,132.0,131.9,131.8,130.6,129.2,128.9,126.2,124.9,124.1,123.1,120.9,116.0,109.3,43.6,26.7,21.4,18.7.HRMS(ESI)m/z:[M+Na]+Calcd for C23H20N2NaO3 395.1366；found 395.1371.
2-Benzyl-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3u)
Yellow solid(78.2mg,62％),mp 213.4-214.3℃.1H NMR(400MHz,CDCl3):δ7.94(s,1H),7.90(s,1H),7.83-7.79(m,2H),7.52-7.47(m,2H),7.41-7.37(m,1H),7.32-7.23(m,4H),7.21-7.16(m,4H),5.54(s,1H),4.08(s,2H),1.29(s,3H),1.13(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,151.4,146.4,140.7,139.9,131.8,131.6,131.2,129.9,128.9,128.74,128.71,128.5,127.9,127.1,126.2,124.9,124.7,122.8,119.1,115.9,109.1,43.6,42.3,21.4,18.7.HRMS(ESI)m/z:[M+H]+Calcdfor C28H25N2O2 421.1911；found421.1910.
8,8-Dimethyl-2-phenyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3v)
Light brown solid(64.6mg,53％),mp 146.8-147.7℃.1H NMR(600MHz,CDCl3):δ8.33(d,J＝0.6Hz,1H),8.16(s,1H),7.97(d,J＝9.0Hz,1H),7.87(d,J＝9.0Hz,1H),7.76(dd,J1＝8.4Hz,J2＝1.2Hz,1H),7.64-7.61(m,3H),7.50-7.49(m,1H),7.45(t,J＝7.8Hz,2H),7.43-7.40(m,1H),7.36(t,J＝7.2Hz,1H),7.28(d,J＝9.0Hz,1H),7.24(td,J1＝7.8Hz,J2＝1.2Hz,1H),5.52(s,1H),1.29(s,3H),1.15(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,151.6,146.6,141.1,139.7,131.9,131.8,131.7,129.9,129.1,128.9,128.6,127.6,127.5,125.3,124.7,123.6,123.0,119.8,116.0,109.2,43.6,21.4,18.8.HRMS(ESI)m/z:[M+Na]+Calcd for C27H22N2NaO2 429.1573；found 429.1574.
2-Methoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3w)
White solid(78.9mg,73％),mp 261.1-262.1℃.1H NMR(600MHz,CDCl3):δ7.82-7.79(m,2H),7.64(dd,J1＝7.8Hz,J2＝1.8Hz,1H),7.53-7.51(m,1H),7.47(d,J＝2.4Hz,1H),7.43-7.40(m,1H),7.28(s,1H),7.24(td,J1＝7.8Hz,J2＝1.2Hz,1H),7.18(d,J＝8.4Hz,1H),7.15(dd,J1＝9.0Hz,J2＝2.4Hz,1H),5.58(s,1H),3.81(s,3H),1.33(s,3H),1.15(s,3H).13C{1H}NMR(100MHz,CDCl3):δ178.2,158.7,151.9,146.5,132.9,131.3,130.11,130.07,128.7,128.1,127.0,125.0,122.9,118.0,117.2,116.0,109.2,104.2,55.3,43.5,21.4,18.7.HRMS(ESI)m/z:[M+H]+Calcd for C22H21N2O3 361.1547；found361.1542.
2-Ethoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3x)
White solid(84.2mg,75％),mp 217.8-218.7℃.1H NMR(400MHz,CDCl3):δ7.82(s,1H),7.79-7.77(m,2H),7.62(d,J＝7.2Hz,1H),7.49(d,J＝8.0Hz,1H),7.44(d,J＝2.0Hz,1H),7.40(t,J＝7.2Hz,1H),7.23(t,J＝7.6Hz,1H),7.14(d,J＝8.8Hz,2H),5.53(s,1H),4.10-4.02(m,1H),4.01-3.94(m,1H),1.42(t,J＝7.2Hz,3H),1.30(s,3H),1.13(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.4,158.0,151.9,146.5,132.9,131.3,130.1,130.0,128.7,128.0,127.0,125.0,122.8,118.3,117.1,116.0,109.1,105.0,63.5,43.6,21.4,18.7,14.8.HRMS(ESI)m/z:[M+H]+Calcd for C23H23N2O3 375.1703；found 375.1694.
2-Bromo-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3y)
White solid(67.3mg,55％),mp 275.1-275.6℃.1H NMR(400MHz,DMSO-d6):δ10.2(s,1H),8.15-8.11(m,2H),8.06(d,J＝8.4Hz,1H),7.71(d,J＝8.4Hz,1H),7.54-7.49(m,3H),7.43(d,J＝8.0Hz,1H),7.28(t,J＝7.2Hz,1H),5.66(s,1H),1.22(s,3H),0.97(s,3H).13C{1H}NMR(150MHz,DMSO-d6):δ176.3,152.3,147.5,132.4,131.7,131.5,131.1,130.9,129.7,129.0,127.8,127.1,123.4,122.9,121.5,121.4,116.6,108.8,43.4,21.5,19.2.HRMS(ESI)m/z:[M+H]+Calcd for C21H18BrN2O2 409.0546；found 409.0543.
2-Benzyl-8,8,14-trimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3z)
White solid(78.2mg,60％),mp 184.9-185.7℃.1H NMR(400MHz,DMSO-d6):δ7.92(s,2H),7.79(d,J＝8.4Hz,2H),7.35-7.32(m,2H),7.29-7.23(m,4H),7.21-7.16(m,4H),5.49(s,1H),4.07(s,2H),2.33(s,3H),1.27(s,3H),1.12(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,151.4,144.0,140.7,140.0,132.5,132.2,131.7,131.2,129.8,129.3,129.0,128.7,128.6,128.0,127.1,126.3,124.9,124.5,119.2,115.9,108.9,43.5,42.4,21.5,20.8,18.8.HRMS(ESI)m/z:[M+H]+Calcd for C29H27N2O2 435.2067；found 435.2064.
2,14-Dimethoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3aa)
Brown solid(71.4mg,61％),mp 228.3-229.2℃.1H NMR(400MHz,CDCl3):δ7.82-7.79(m,2H),7.54-7.52(m,2H),7.41(d,J＝8.8Hz,1H),7.23(d,J＝2.8Hz,1H),7.19-7.14(m,2H),6.96(dd,J1＝8.8Hz,J2＝2.4Hz,1H),5.51(s,1H),3.82(s,6H),1.31(s,3H),1.14(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.5,158.7,155.6,152.0,139.9,132.7,130.2,128.0,126.9,126.0,118.1,117.4,117.1,116.7,114.1,108.7,104.0,55.7,55.3,43.3,21.7,18.8.HRMS(ESI)m/z:[M+H]+Calcd for C23H23N2O4 391.1652；found 391.1653.
2-Ethoxy-14-methoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3bb)
Brown solid(52.1mg,43％),mp 125.6-126.5℃.1H NMR(400MHz,CDCl3):δ7.79(d,J＝8.4Hz,2H),7.53(s,1H),7.50(s,1H),7.40(d,J＝8.8Hz,1H),7.21(d,J＝2.4Hz,1H),7.16-7.14(m,2H),6.95(dd,J1＝8.8Hz,J2＝2.8Hz,1H),5.49(s,1H),4.08-3.98(m,2H),3.82(s,3H),1.43(t,J＝6.8Hz,3H),1.30(s,3H),1.13(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.4,158.1,155.6,152.0,139.9,132.8,130.15,130.12,128.0,126.8,126.1,118.4,117.2,117.0,116.8,114.1,108.7,104.8,63.5,55.7,43.3,21.7,18.8,14.8.HRMS(ESI)m/z:[M+H]+Calcd for C24H25N2O4405.1809；found 405.1807.
14-Methoxy-8,8-dimethyl-2-phenyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3cc)
Light brown solid(77.2mg,59％),mp 203.4-204.3℃.1H NMR(600MHz,CDCl3):δ8.38(s,1H),7.98(d,J＝8.4Hz,1H),7.91(d,J＝8.4Hz,1H),7.75(dd,J1＝8.4Hz,J2＝1.8Hz,1H),7.63-7.62(m,2H),7.46-7.41(m,3H),7.38-7.35(m,2H),7.32(d,J＝8.4Hz,1H),7.21(d,J＝3.0Hz,1H),6.97(dd,J1＝9.0Hz,J2＝2.4Hz,1H),5.52(s,1H),3.81(s,3H),1.32(s,3H),1.15(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.3,155.6,151.7,141.0,140.0,139.8,131.72,131.67,130.2,129.2,128.9,128.4,127.6,127.5,125.8,125.3,123.4,119.9,117.6,117.0,114.1,108.9,55.7,43.3,21.7,18.9.HRMS(ESI)m/z:[M+H]+Calcdfor C28H25N2O3 437.1860；found 437.1857.
3-Acetyl-13-chloro-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3dd)
White solid(63.4mg,52％),mp 262.5-263.2℃.1H NMR(600MHz,CDCl3):δ8.52(s,1H),8.10(d,J＝9.0Hz,1H),8.04(d,J＝8.4Hz,2H),7.53(s,2H),7.45(d,J＝8.4Hz,1H),7.41(d,J＝8.4Hz,1H),7.23(dd,J1＝7.8Hz,J2＝1.8Hz,1H),5.61(s,1H),2.74(s,3H),1.34(s,3H),1.18(s,3H).13C{1H}NMR(150MHz,CDCl3):δ197.7,178.1,153.2,147.8,135.2,134.2,133.8,133.0,132.2,131.8,130.6,127.9,125.8,125.2,123.1,122.4,120.8,116.4,109.3,43.8,26.7,21.2,18.8.HRMS(ESI)m/z:[M+Na]+Calcd for C23H19ClN2NaO3429.0976；found 429.0971.
3-Acetyl-13-bromo-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3ee)
Yellow solid(82.4mg,61％),mp 232.3-233.6℃.1H NMR(400MHz,DMSO-d6):δ10.3(s,1H),8.83(s,1H),8.33(d,J＝9.2Hz,1H),8.09-8.04(m,2H),7.60(d,J＝8.8Hz,1H),7.52(s,1H),7.49-7.47(m,2H),5.74(s,1H),2.74(s,3H),1.24(s,3H),1.01(s,3H).13C{1H}NMR(150MHz,DMSO-d6):δ198.1,176.2,153.5,148.9,134.1,133.9,133.3,133.1,131.9,131.6,127.6,125.6,125.4,122.8,122.6,121.7,119.0,108.8,43.6,27.2,21.2,19.2.HRMS(ESI)m/z:[M+H]+Calcd for C23H20BrN2O3451.0652；found 451.0645.
13-Chloro-2-methoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3ff)
White solid(73.3mg,62％),mp 240.7-241.5℃.1H NMR(400MHz,CDCl3):δ8.38(s,1H),7.81-7.78(m,2H),7.55(d,J＝8.0Hz,1H),7.50(d,J＝2.0Hz,1H),7.38(d,J＝2.0Hz,1H),7.20(dd,J1＝8.4Hz,J2＝2.0Hz,1H),7.15(d,J＝8.4Hz,2H),5.55(s,1H),3.82(s,3H),1.32(s,3H),1.17(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.6,158.8,152.0,147.7,134.6,132.8,132.3,130.3,130.2,128.0,126.1,123.3,122.8,118.2,117.1,116.3,109.1,103.8,55.3,43.8,21.2,18.8.HRMS(ESI)m/z:[M+Na]+Calcd forC22H19ClN2NaO3 417.0976；found 417.0973.
13-Chloro-2-ethoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3gg)
White solid(79.6mg,65％),mp 227.7-228.5℃.1H NMR(400MHz,CDCl3):δ7.96(s,1H),7.82-7.78(m,2H),7.54(d,J＝8.0Hz,1H),7.55(d,J＝2.0Hz,1H),7.36(d,J＝2.0Hz,1H),7.20(dd,J1＝8.0Hz,J2＝2.0Hz,1H),7.15(d,J＝8.8Hz,2H),5.57(s,1H),4.11-3.96(m,2H),1.44(t,J＝6.8Hz,3H),1.32(s,3H),1.17(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.5,158.2,152.0,147.7,134.5,132.8,132.3,130.3,130.1,128.0,126.0,123.4,122.8,118.5,117.0,116.3,109.2,104.6,63.5,43.7,21.2,18.8,14.7.HRMS(ESI)m/z:[M+Na]+Calcd for C23H21ClN2NaO3 431.1133；found431.1135.
13-Bromo-2-methoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3hh)
White solid(86.7mg,66％),mp 218.9-219.7℃.1H NMR(400MHz,CDCl3):δ8.17(s,1H),7.82-7.78(m,2H),7.65(s,1H),7.48(d,J＝8.0Hz,1H),7.37-7.34(m,2H),7.16(d,J＝8.8Hz,2H),5.56(s,1H),3.82(s,3H),1.32(s,3H),1.17(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.5,158.9,152.0,147.8,132.7,132.5,130.4,130.2,128.0,126.1,125.8,123.9,122.6,119.2,118.2,117.1,109.2,103.8,55.3,43.8,21.2,18.8.HRMS(ESI)m/z:[M+H]+Calcd for C22H20BrN2O3 439.0652；found 439.0650.
13-Bromo-2-ethoxy-8,8-dimethyl-7a,8-dihydrobenzo[d]naphtho[1,2-f]pyrazolo[5,1-b][1,3]oxazepin-9(10H)-one(3ii)
Yellow solid(74.6mg,55％),mp 229.8-228.5℃.1H NMR(600MHz,CDCl3):δ8.00(s,1H),7.81-7.78(m,2H),7.64(d,J＝1.8Hz,1H),7.47(d,J＝8.4Hz,1H),7.35-7.34(m,2H),7.16-7.14(m,2H),5.56(s,1H),4.08-4.04(m,1H),4.02-3.98(m,1H),1.44(t,J＝7.2Hz,3H),1.32(s,3H),1.17(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.5,158.2,151.9,147.8,132.8,132.6,130.4,130.1,128.0,126.0,125.8,123.9,122.5,119.1,118.5,117.0,109.2,104.6,63.6,43.8,21.2,18.8,14.7.HRMS(ESI)m/z:[M+H]+Calcd forC23H22BrN2O3 453.0808；found 453.0813.
实施例4
本发明所合成的产物吡唑烷酮并苯并1,3-氧氮杂卓类化合物3可以进行一系列反应，从而合成进一步的衍生物。例如：
Figure BDA0003045535120000171
在0℃下，向3a(66.0mg，0.2mmol)的DMF(0.5mL)溶液中添加氢化钠(5.8mg，0.24mmol)/DMF(1mL)溶液并搅拌15分钟，然后在室温条件下将混合物搅拌1小时。随后，将反应混合物冷却至0℃，向反应体系内滴加碘甲烷(15μL,0.24mmol)，滴加完毕后，将混合物恢复至室温并持续搅拌30分钟。反应结束后，再次将混合物冷却至0℃，加入饱和氯化铵溶液淬灭反应，并用乙酸乙酯萃取，合并有机相，用无水硫酸钠干燥，过滤，旋干，过硅胶柱分离(石油醚/乙酸乙酯＝3/1)得到白色固体产物4(34.4mg，50％)。该化合物的表征数据如下：1H NMR(400MHz,CDCl3):δ8.20-8.18(m,1H),7.93-7.89(m,2H),7.61(d,J＝7.6Hz,1H),7.53-7.47(m,2H),7.43-7.39(m,1H),7.33(d,J＝8.8Hz,1H),7.26-7.23(m,1H),7.07(d,J＝8.0Hz,1H),5.52(s,1H),3.10(s,3H),1.32(s,3H),1.12(s,3H).13C{1H}NMR(100MHz,CDCl3):δ176.0,151.2,144.6,132.6,132.2,131.4,130.2,128.63,128.60,128.4,126.8,125.7,125.6,125.4,122.9,119.8,116.4,108.2,44.1,31.5,22.1,18.6.HRMS(ESI)m/z:[M+H]+Calcd for C22H21N2O2345.1598；found 345.1587.
Figure BDA0003045535120000172
向15mL反应瓶中依次加入3h(39.5mg，0.1mmol)、乙炔基苯(16.5μL，0.15mmol)、PPh3(5.2mg，0.02mmol)、K3PO4(25.5mg，0.12mmol)、Pd(OAc)2(1.1mg，0.005mmol)和DMSO(1mL)，并将所得混合物在80℃、氩气氛围下搅拌24小时。反应结束后，用乙酸乙酯萃取，合并有机相，用无水硫酸钠干燥，过滤，旋干，过硅胶柱分离(石油醚/乙酸乙酯＝3/1)得到白色固体产物5(33mg，77％)。该化合物的表征数据如下：1H NMR(400MHz,CDCl3):δ8.15(d,J＝8.4Hz,1H),7.92-7.89(m,2H),7.75(d,J＝1.6Hz,1H),7.68(s,1H),7.59(dd,J1＝8.4Hz,J2＝1.6Hz,1H),7.56-7.47(m,5H),7.35-7.30(m,4H),5.58(s,1H),1.32(s,3H),1.15(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.2,151.4,146.6,135.1,132.6,132.1,131.6,131.4,130.6,128.6,128.4,128.2,127.5,127.3,125.6,125.4,124.7,123.3,119.6,117.7,116.0,109.4,89.3,89.0,43.8,21.2,18.7.HRMS(ESI)m/z:[M+H]+Calcd for C29H23N2O2431.1754；found 431.1740.
Figure BDA0003045535120000181
向15mL反应管中依次加入3h(40.8mg，0.1mmol)、苯基硼酸(24.4mg，0.2mmol)、PPh3(15.7mg，0.06mmol)、K2CO3(55.3mg，0.4mmol)、Pd(OAc)2(2.2mg，0.01mmol)和1,4-二氧六环(1mL)。将所得混合物在氩气氛围中于80℃搅拌反应24小时。反应结束后，用乙酸乙酯萃取，合并有机相，用无水硫酸钠干燥，过滤，旋干，过硅胶柱分离(石油醚/乙酸乙酯＝3/1)得到白色固体产物6(26.9mg，66％)。该化合物的表征数据如下：1H NMR(600MHz,CDCl3):δ8.19-8.17(m,1H),7.93-7.89(m,2H),7.83(d,J＝1.8Hz,2H),7.65(dd,J1＝8.4Hz,J2＝1.8Hz,1H),7.62(d,J＝7.2Hz,2H)7.56(d,J＝8.4Hz,1H),7.51-7.48(m,2H),7.43(t,J＝7.2Hz,2H),7.35-7.32(m,2H),5.58(s,1H),1.33(s,3H),1.19(s,3H).13C{1H}NMR(150MHz,CDCl3):δ178.2,151.4,145.8,140.2,135.7,132.7,131.6,130.6,130.4,128.9,128.7,128.3,127.3,127.17,127.15,126.8,125.5,124.9,119.8,116.4,109.2,43.7,21.4,18.9.HRMS(ESI)m/z:[M+Na]+Calcd for C27H22N2NaO2 429.1573；found 429.1583.
Figure BDA0003045535120000191
在0℃下，向3a(66.0mg，0.2mmol)的乙酸乙酯(2mL)和甲醇(0.2mL)混合溶液中，分批加入硼氢化钠(15.1mg，0.4mmol)，然后将该混合物在0℃搅拌反应10小时。反应结束后，加入饱和碳酸氢钠溶液淬灭反应，用乙酸乙酯萃取。合并有机相，用无水硫酸钠干燥，过滤，旋干，过硅胶柱分离(石油醚/乙酸乙酯＝3/1)得到白色固体产物V(29.9mg，45％)。该化合物的表征数据如下：1H NMR(600MHz,CDCl3):δ7.85(t,J＝9.0Hz,2H),7.77(s,1H),7.59(d,J＝7.8Hz,1H),7.54(d,J＝7.8Hz,1H),7.46-7.43(m,1H),7.42-7.38(m,2H),7.37-7.35(m,1H),7.29(d,J＝8.4Hz,1H),7.23(t,J＝7.2Hz,1H),3.19(d,J＝11.4Hz,1H),2.94(d,J＝11.4Hz,1H),1.02(s,3H),0.99(s,3H).13C{1H}NMR(100MHz,CDCl3):δ179.6,150.6,149.9,135.0,133.3,130.0,129.8,129.2,128.3,126.7,126.1,124.7,124.2,123.6,119.6,119.5,116.2,67.5,40.4,24.1,22.8.HRMS(ESI)m/z:[M+Na]+Calcd for C21H20N2NaO2355.1417；found 355.1406.
以上实施例描述了本发明的基本原理、主要特征及优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明原理的范围下，本发明还会有各种变化和改进，这些变化和改进均落入本发明保护的范围内。

Claims (9)

1.一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于，包括如下操作：以1-芳基吡唑烷酮1和重氮萘酮类化合物2为原料，在催化剂、氧化剂和添加剂存在下，有机溶剂中升温反应得到吡唑烷酮并苯并1,3-氧氮杂卓类化合物3，反应方程式为：
Figure FDA0003045535110000011
其中R1为氢、卤素、三氟甲基、氰基、C1-4烷基、C1-4烷氧基或苄氧基，R2为氢、卤素、氰基、乙酰基、苄基、C1-4烷基、C1-4烷氧基、苯基或取代苯基，取代苯基的取代基为卤素、三氟甲基、氰基、乙酰基、C1-4烷基或C1-4烷氧基。
2.根据权利要求1所述吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于：反应溶剂为1,2-二氯乙烷、二氯甲烷、乙腈或甲苯。
3.根据权利要求1所述吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于：所述氧化剂为醋酸银、过氧化银、三氟乙酸银、碳酸银、氧化铜、醋酸铜或硫酸铜。
4.根据权利要求1所述吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于：所述添加剂为醋酸、三甲基乙酸、2,4,6-三甲基苯甲酸或1-金刚烷甲酸。
5.根据权利要求1所述吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于：所述催化剂为[RhCp*Cl2]2、RhCp*(OAc)2、RhCp*(MeCN)3(SbF6)2或[IrCp*Cl2]2。
6.根据权利要求1所述吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于：所述1-芳基吡唑烷酮1、重氮萘酮类化合物2、氧化剂、添加剂和催化剂的投料摩尔比为1:1-1.5:1.0-2.5:0.5-3.0:0.025。
7.根据权利要求1所述吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于：所述反应温度为60-120℃。
8.根据权利要求1-7任意一项所述吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于：反应中添加分子筛。
9.根据权利要求1-7任意一项所述吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法，其特征在于：反应在氩气氛围下进行。
CN202110471374.1A 2021-04-29 2021-04-29 一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法 Active CN113185536B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110471374.1A CN113185536B (zh) 2021-04-29 2021-04-29 一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110471374.1A CN113185536B (zh) 2021-04-29 2021-04-29 一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法

Publications (2)

Publication Number Publication Date
CN113185536A true CN113185536A (zh) 2021-07-30
CN113185536B CN113185536B (zh) 2022-06-17

Family

ID=76980376

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110471374.1A Active CN113185536B (zh) 2021-04-29 2021-04-29 一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法

Country Status (1)

Country Link
CN (1) CN113185536B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114133360A (zh) * 2021-11-30 2022-03-04 南京工业大学 一种含氟苯并[d]-1,3-氧氮杂卓化合物及其合成方法
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106588747A (zh) * 2016-11-24 2017-04-26 河南师范大学 一种芳环并[a]咔唑类化合物的合成方法
CN108997298A (zh) * 2018-06-28 2018-12-14 河南师范大学 一种萘并[1,8-bc]吡喃类化合物的合成方法
CN111138430A (zh) * 2020-02-10 2020-05-12 河南师范大学 一种含咪唑稠杂环类化合物的合成方法
CN111233872A (zh) * 2020-03-20 2020-06-05 西北工业大学 一种萘并三氮唑并二氮杂卓酮类化合物的制备方法
CN111471047A (zh) * 2020-05-21 2020-07-31 河南师范大学 选择性合成吡唑并[1,2-a]吡唑酮或2-酰基吲哚类化合物的方法
CN111675712A (zh) * 2020-06-23 2020-09-18 河南师范大学 一种吡唑啉酮并苯二氮杂卓类化合物的合成方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106588747A (zh) * 2016-11-24 2017-04-26 河南师范大学 一种芳环并[a]咔唑类化合物的合成方法
CN108997298A (zh) * 2018-06-28 2018-12-14 河南师范大学 一种萘并[1,8-bc]吡喃类化合物的合成方法
CN111138430A (zh) * 2020-02-10 2020-05-12 河南师范大学 一种含咪唑稠杂环类化合物的合成方法
CN111233872A (zh) * 2020-03-20 2020-06-05 西北工业大学 一种萘并三氮唑并二氮杂卓酮类化合物的制备方法
CN111471047A (zh) * 2020-05-21 2020-07-31 河南师范大学 选择性合成吡唑并[1,2-a]吡唑酮或2-酰基吲哚类化合物的方法
CN111675712A (zh) * 2020-06-23 2020-09-18 河南师范大学 一种吡唑啉酮并苯二氮杂卓类化合物的合成方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张凌华 等: "吡唑啉酮并苯并二氮杂卓类化合物的高效合成", 《河南省化学会2020年学术年会》, 30 October 2020 (2020-10-30), pages 1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114133360A (zh) * 2021-11-30 2022-03-04 南京工业大学 一种含氟苯并[d]-1,3-氧氮杂卓化合物及其合成方法
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Also Published As

Publication number Publication date
CN113185536B (zh) 2022-06-17

Similar Documents

Publication Publication Date Title
CN113185536B (zh) 一种吡唑烷酮并苯并1,3-氧氮杂卓类化合物的合成方法
CN111471047B (zh) 选择性合成吡唑并[1,2-a]吡唑酮或2-酰基吲哚类化合物的方法
EP1727797B1 (en) Process for cross coupling indoles
CN110437124B (zh) 一种吲哚醌衍生物的制备方法
CN106046002B (zh) 一种吡啶并咪唑并[1,2,3]三氮唑并喹啉类化合物的合成方法
CN114014805B (zh) 三氟甲基化2,4-喹啉二酮类化合物的制备方法
CN114773294A (zh) 一种依布硒啉类化合物的制备方法
CN115197228A (zh) 吡唑啉酮[螺]二氢酞嗪和1,3-茚二酮[螺]二氢酞嗪类化合物的合成方法
CN115124542A (zh) 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法
Xia et al. Palladium-Catalyzed Decarboxylative Csp 2–Csp 2 Cross-Coupling Reactions: An Efficient Route for Synthesis of Azaisoflavone Derivatives
CN108164483A (zh) 一种新的五元芳杂环和芳环并五元芳杂环芳基化合成方法
CN108929262B (zh) 一种苯并[a]咔唑类化合物的合成方法
CN108424380B (zh) 一种合成3h-吲哚-3-酮类衍生物的方法
CN109942587B (zh) 色酮并喹啉杂环化合物的制备方法
EP1849777B1 (en) Process for obtaining a valsartan salt useful for obtaining valsartan
CN113717107B (zh) N-酰基苯并咪唑类化合物的合成方法
CN111592549B (zh) 一种喹唑啉酮衍生物的制备方法
CN109810036B (zh) 4-氧代-5-(芳甲酰基乙酸酯-2-基)萘-亚砜叶立德杂化体的合成方法
CN110423215B (zh) 一种查尔酮吡啶盐及其制备方法和应用
CN114230528B (zh) 一种制备喹喔啉酮衍生物的方法
CN113402446B (zh) 一种3-氨基4-羟基咔唑类化合物、制备方法及应用
JP2549931B2 (ja) ピリミドベンズイミダゾール誘導体
CN109810112B (zh) 一种吲哚并[2,1-a]酞嗪衍生物的制备方法
CN116063318A (zh) 一种瑞卢戈利及其中间体的制备方法
CN114409713A (zh) 一种n-非取代二茂铁并吡啶酮衍生物及其合成方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant